MAIC Points to Improved OS With Momelotinib in Ruxolitinib-Pretreated Myelofibrosis
Momelotinib improved OS vs best available therapy in patients with ruxolitinib-experienced myelofibrosis, according to data from a MAIC analysis.
Related Articles
NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers
NRG1 fusion positivity has gained interest as a treatment target in lung and pancreatic cancer, leading to the FDA approval of zenocutuzumab in December 2024.
Job Opportunity at University of Leeds: Research Fellow
Are you an ambitious researcher looking for your next challenge? Do you have a background in economics, econometrics, statistics, epidemiology or health data science? Are…
The Lancet Oncology
Access articles from The Lancet Oncology, covering topics that advance clinical practice, challenge the status quo, advocate change in health policy, and tackle issues related…
Outcomes of teclistamab in RRMM with prior exposure to BCMA-directed therapy
Jack Khouri, MD, Cleveland Clinic, Cleveland, OH, comments on a study investigating the outcomes of teclistamab treatment in patients with relapsed/refractory multiple myeloma (RRMM) who…
Haplotype analysis detects MLH1 founder variant in Indian Lynch syndrome patient cohort – PubMed
Lynch syndrome (LS) is an autosomal dominant hereditary cancer predisposition syndrome whereby the lifetime risk of developing gastrointestinal and genitourinary cancers rises by to over…
Sarcoma Updates from ESMO 2024: Insights from Dr. Herbert Loong
Herbert Loong, Clinical Associate Professor in the Department of Clinical Oncology at the Chinese University of Hong Kong, discusses key sarcoma updates from…
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS
Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care.
Expanding JAK Inhibitor Arsenal Provides Additional Options Beyond Ruxolitinib in Myelofibrosis
Aaron Gerds, MD, discusses differences in molecular targets, efficacy, and toxicity profiles between available JAK inhibitors in myelofibrosis.
Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT
Orca-Q led to low rates of graft-vs-host disease and non-relapse mortality in high-risk hematologic malignancies undergoing allo-HCT.